Treatment Trials

1 Clinical Trials for Various Conditions

Focus your search

      ACTIVE_NOT_RECRUITING
      Tovorafenib (DAY101) Monotherapy or in Combination With Other Therapies for Patients With Melanoma and Other Solid Tumors
      Description

      This is a Phase 1b/2, multi-center, open label umbrella study of patients ≥12 years of age with recurrent, progressive, or refractory melanoma or other solid tumors with alterations in the key proteins of the RAS/RAF/MEK/ERK pathway, referred to as the MAPK pathway.

      Conditions
      MelanomaSolid TumorCRAF Gene AmplificationRAF1 Gene AmplificationBRAF Gene FusionBRAF FusionCRAF Gene FusionCRAF FusionRAF1 Gene FusionRAF1 FusionThyroid Cancer, PapillarySpitzoid MelanomaPilocytic AstrocytomaPilocytic Astrocytoma, AdultNon Small Cell Lung CancerNon-Small Cell AdenocarcinomaColorectal CancerPancreatic Acinar CarcinomaSpitzoid Malignant MelanomaBladder CancerBladder Urothelial CarcinomaMAP Kinase Family Gene MutationRAS MutationRAF MutationMEK Mutation
      Talk to us